Találati lista | Tudóstér

001-es BibID:	BIBFORM105181
035-os BibID:	(WOS)000887302300001 (Scopus)85142806190
Első szerző:	Juhász Lilla (általános orvos)
Cím:	Sphingosine 1-Phosphate and Apolipoprotein M Levels and Their Correlations with Inflammatory Biomarkers in Patients with Untreated Familial Hypercholesterolemia / Juhász Lilla, Lőrincz Hajnalka, Szentpéteri Anita, Nádró Bíborka, Varga Éva, Paragh György, Harangi Mariann
Dátum:	2022
ISSN:	1422-0067
Megjegyzések:	High-density lipoprotein (HDL)-bound apolipoprotein M/sphingosine 1-phosphate (ApoM/S1P) complex in cardiovascular diseases serves as a bridge between HDL and endothe lial cells, maintaining a healthy endothelial barrier. To date, S1P and ApoM in patients with untreated heterozygous familial hypercholesterolemia (HeFH) have not been extensively studied. Eighty-one untreated patients with HeFH and 32 healthy control subjects were included in this study. Serum S1P, ApoM, sCD40L, sICAM-1, sVCAM-1, oxLDL, and TNF? concentrations were determined by ELISA. PON1 activities were measured spectrophotometrically. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Significantly higher serum S1P and ApoM levels were found in HeFH patients compared to controls. S1P negatively correlated with large HDL and positively with small HDL subfractions in HeFH patients and the whole study population. S1P showed significant positive correlations with sCD40L and MMP-9 levels and PON1 arylesterase activity, while we found significant negative correlation between sVCAM-1 and S1P in HeFH patients. A backward stepwise multiple regression analysis showed that the best predictors of serum S1P were large HDL subfraction and arylesterase activity. Higher S1P and ApoM levels and their correlations with HDL subfractions and inflammatory markers in HeFH patients implied their possible role in endothelial protection.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk sphingosine 1-phosphate familial hypercholesterolemia sCD40 ligand apolipoprotein M soluble vascular adhesion molecule-1 arylesterase activity high-density lipoprotein inflammation
Megjelenés:	International Journal Of Molecular Sciences. - 23 (2022), p. 1-12. -
További szerzők:	Lőrincz Hajnalka (1986-) (biológus) Szentpéteri Anita (1988-) (biológus) Nádró Bíborka (1992-) (általános orvos) Varga Éva (1982-) (belgyógyász) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:	OTKA-142273 OTKA TKP2021-EGA-18 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM133501
Első szerző:	Nádró Bíborka (általános orvos)
Cím:	Diagnostic and Therapeutic Challenges of Homozygous and Severe Heterozygous Familial Hypercholesterolemia from Clinical Aspect : A Single-Center Study / Nádró Bíborka, Kaluha Judit, Lőrincz Hajnalka, Varga Éva, Balogh István, Harangi Mariann
Dátum:	2025
ISSN:	2077-0383
Megjegyzések:	Background/Objectives: The clinical presentation of homozygous familial hypercholesterolemia (HoFH) and severe heterozygous familial hypercholesterolemia (sHeFH) often demonstrates substantial overlap, as low-density lipoprotein cholesterol (LDL-C) levels may fall within similar ranges in both conditions. Methods: In this single-center 10-year retrospective study at the University of Debrecen, Hungary, we present the clinical characteristics of patients with 6 HoFH and 6 sHeFH diagnosed by genetic testing, discuss the diagnostic limitations encountered in clinical practice, and outline the key components of therapeutic management. Results: The mean age at diagnosis was lower in the HoFH group (31.83 ? 19.5 vs. 41.83 ? 15.9 years). The differences in total cholesterol (13.48 ? 7.4 vs. 11.02 ? 3.5 mmol/L) and LDL-C levels (10.89 ? 6.6 vs. 8.58 ? 3.26 mmol/L) between the groups were not statistically significant. Interestingly, vascular complications were more frequent in sHeFH group as well (4 vs. 1 patients). In neither the HoFH nor the sHeFH group were we able to achieve the target LDL-C levels, due in part to the specific features of the reimbursement system, patient and parental preferences, the extremely high baseline LDL-C levels, and certain genetic characteristics. Conclusions: Our findings highlight the importance of genetic testing-based personalized therapy in these specific patient subpopulations. We emphasize that serum LDL-C alone is insufficient to distinguish between HoFH and sHeFH patients, and that therapeutic challenges should be anticipated in both groups arising partly from limited patient adherence as well as from financial constraints.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk familial hypercholesterolemia homozygous heterozygous low-density lipoprotein cholesterol genetic testing lipid-lowering therapies therapy resistance personalized medicine
Megjelenés:	Journal of Clinical Medicine. - 14 : 22 (2025), p. 1-15. -
További szerzők:	Kaluha Judit (1987-) (orvos) Lőrincz Hajnalka (1986-) (biológus) Varga Éva (1982-) (belgyógyász) Balogh István (1972-) (molekuláris biológus, genetikus) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:	K142273 OTKA TKP2021-EGA-18 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM101082
035-os BibID:	(WoS)000786951400001 (Scopus)85128385089
Első szerző:	Nádró Bíborka (általános orvos)
Cím:	Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia / Bíborka Nádró, Hajnalka Lőrincz, Lilla Juhász, Anita Szentpéteri, Ferenc Sztanek, Éva Varga, Dénes Páll, György Paragh, Mariann Harangi
Dátum:	2022
ISSN:	2227-9059
Megjegyzések:	Abstract: Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that is known to have various anti-atherogenic effects. To date, the use of serum PGRN in patients with FH has not been studied. Methods: In total, 81 untreated patients with heterozygous FH (HeFH) and 32 healthy control subjects were included in this study. Serum PGRN, sICAM-1, sVCAM-1, oxLDL and TNF concentrations were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Results: We could not find a significant difference between the PGRN concentrations of the HeFH patients and controls (37.66 9.75 vs. 38.43 7.74 ng/mL, ns.). We found significant positive correlations between triglyceride, TNF , sVCAM-1, the ratio of small HDL subfraction and PGRN, while significant negative correlations were found between the ratio of large HDL subfraction and PGRN both in the whole study population and in FH patients. PGRN was predicted by sVCAM-1, logTNF and the ratio of small HDL subfraction. Conclusions: The strong correlations between HDL subfractions, inflammatory markers and PGRN suggest that PGRN may exert its anti-atherogenic effect in HeFH through the alteration of HDL composition and the amelioration of inflammation rather than through decreasing oxidative stress.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk progranulin familial hypercholesterolemia inflammation tumor necrosis factor alpha high-density lipoprotein subfraction
Megjelenés:	Biomedicines. - 10 : 4 (2022), p. 1-15. -
További szerzők:	Lőrincz Hajnalka (1986-) (biológus) Juhász Lilla (1990-) (általános orvos) Szentpéteri Anita (1988-) (biológus) Sztanek Ferenc (1982-) (orvos) Varga Éva (1982-) (belgyógyász) Páll Dénes (1967-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:	OTKA-115723 OTKA GINOP-2.3.2-15-2016-00062 GINOP Bridging Fund, Faculty of Medicine, University of Debrecen - HM Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: